March 28 (Reuters) - Amgen Inc AMGN.O:
AMGEN: PHASE 3 VESALIUS-CV CLINICAL TRIAL SHOWED REPATHA REDUCED RISKS OF HEART ATTACK, CORONARY HEART DISEASE DEATH, ISCHEMIC STROKE
AMGEN: REPATHA CUTS RISK OF FIRST MAJOR CARDIOVASCULAR EVENT BY 31% IN HIGH-RISK PATIENTS WITHOUT KNOWN SIGNIFICANT ATHEROSCLEROSIS
Source text: [ID:]